Graduate Program in Principles of Surgery, Mackenzie Evangelical University, Curitiba 80730-000, PR, Brazil.
The Center for Advanced Neurology and Neurosurgery (CEANNE), Porto Alegre 90560-010, RS, Brazil.
Int J Mol Sci. 2024 Mar 5;25(5):3020. doi: 10.3390/ijms25053020.
Gliomas comprise most cases of central nervous system (CNS) tumors. Gliomas afflict both adults and children, and glioblastoma (GBM) in adults represents the clinically most important type of malignant brain cancer, with a very poor prognosis. The cell surface glycoprotein CD114, which is encoded by the gene, acts as the receptor for the granulocyte colony stimulating factor (GCSF), and is thus also called GCSFR or CSFR. CD114 is a marker of cancer stem cells (CSCs), and its expression has been reported in several cancer types. In addition, CD114 may represent one among various cases where brain tumors hijack molecular mechanisms involved in neuronal survival and synaptic plasticity. Here, we describe mRNA expression in human gliomas and their association with patient prognosis as assessed by overall survival (OS). We found that the levels of /CD114 transcripts are higher in a few different types of gliomas, namely astrocytoma, pilocytic astrocytoma, and GBM, in comparison to non-tumoral neural tissue. We also observed that higher expression of /CD114 in gliomas is associated with poorer outcome as measured by a shorter OS. Our findings provide early evidence suggesting that /CD114 shows a potential role as a prognosis marker of OS in patients with GBM.
神经胶质瘤是中枢神经系统（CNS）肿瘤的主要类型。神经胶质瘤可发生于成人和儿童，成人的胶质母细胞瘤（GBM）是临床上最重要的恶性脑癌类型，预后极差。细胞表面糖蛋白 CD114 由 基因编码，是粒细胞集落刺激因子（GCSF）的受体，因此也称为 GCSFR 或 CSFR。CD114 是癌症干细胞（CSC）的标志物，已在多种癌症类型中报道过其表达。此外，CD114 可能代表了多种情况之一，即脑肿瘤劫持了涉及神经元存活和突触可塑性的分子机制。在这里，我们描述了人类神经胶质瘤中的 mRNA 表达及其与总生存期（OS）评估的患者预后的关系。我们发现，与非肿瘤性神经组织相比，在几种不同类型的神经胶质瘤（星形细胞瘤、毛细胞星形细胞瘤和 GBM）中，/CD114 转录本的水平更高。我们还观察到，神经胶质瘤中 /CD114 的高表达与 OS 较短的不良预后相关。我们的研究结果提供了早期证据，表明 /CD114 作为胶质母细胞瘤患者 OS 预后标志物具有潜在作用。
